Alcon offers to take over biotech firm ESBATech

09/14/2009 | Reuters

Alcon is in a definitive agreement to acquire ESBATech, a clinical-stage biotech firm in Switzerland, for $150 million in cash and as much as $439 million in milestone dues. The deal would give Alcon access to ESBATech's eye treatment technology and expand its research capability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park